Company profile: Xencor
1.1 - Company Overview
Company description
- Provider of monoclonal antibody therapeutics and an antibody engineering platform. The XmAb Protein Engineering Platform improves potency, half-life and stability via Fc-domain engineering. Offerings include Monjuvi (tafasitamab-cxix) with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma, and clinical bispecifics vudalimab, XmAb819, XmAb808 and XmAb541 for cancer and in autoimmune, asthma and allergic diseases.
Products and services
- Monjuvi® (tafasitamab-cxix): Indication-specific, CD19-directed cytolytic antibody administered with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma, enabling targeted B-cell depletion
- XmAb® Protein Engineering Platform: Custom-engineered Fc-domain platform that enhances antibody candidates’ potency, extends half-life, and improves stability by precise Fc engineering for therapies targeting autoimmune disorders, asthma, allergic diseases, and cancer
- Vudalimab: Clinical-stage bispecific antibody targeting PD-1 and CTLA-4 to promote tumor-selective T-cell activation, under clinical trials for prostate and lung cancer indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xencor
Hookipa Pharma
HQ: United States
Website
- Description: Provider of arenavirus-based immunotherapies for infectious diseases and cancer, using proprietary TheraT and Vaxwave vector platforms to elicit neutralizing antibodies and T cell responses. Offerings include HB-200 for HPV-associated head and neck cancers, HB-700 for KRAS-mutated cancers, and replicating and non-replicating technologies for oncology and prophylactic immunization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hookipa Pharma company profile →
Hepion Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical drug development, featuring rencofilstat, a cyclophilin inhibitor aimed at reducing liver fibrosis and hepatocellular carcinoma tumor burden, currently in Phase 2 for NASH, and a proprietary AI/ML platform to understand disease processes and identify patients who respond to rencofilstat, potentially shortening development timelines and enhancing clinical trial outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hepion Pharmaceuticals company profile →
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Jennerex
HQ: United States
Website
- Description: Provider of targeted oncolytic products for cancer, focused on development and commercialization of first-in-class therapies. Lead candidate Pexa-Vec (JX-594), a targeted oncolytic virus that selectively infects and destroys cancer cells, is in international Phase 2 trials for primary liver and colorectal cancers after promising Phase 1 efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jennerex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xencor
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xencor
2.2 - Growth funds investing in similar companies to Xencor
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xencor
4.2 - Public trading comparable groups for Xencor
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →